SAN FRANCISCO – A study presented at a late-breaking clinical trial session at the Heart Rhythm Society annual meeting suggests that patients who are already on amiodarone now have a choice of drug and device therapy if their current dosage level fails to keep their ventricular tachycardia (VT) under control. Read More
